Orexo AB (publ) (ORX.ST)
SEK 14.96
(0.81%)
SEK 14.96
(0.81%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 302.8 Million SEK | -25.68% |
| 2022 | 407.4 Million SEK | 778.02% |
| 2021 | 46.4 Million SEK | 121.65% |
| 2020 | -214.3 Million SEK | 54.65% |
| 2019 | -472.5 Million SEK | -75.52% |
| 2018 | -269.2 Million SEK | -2994.25% |
| 2017 | -8.7 Million SEK | -107.54% |
| 2016 | 115.4 Million SEK | -61.04% |
| 2015 | 296.21 Million SEK | 41.54% |
| 2014 | 209.28 Million SEK | 13498.34% |
| 2013 | -1.56 Million SEK | 98.64% |
| 2012 | -114.49 Million SEK | 13.49% |
| 2011 | -132.34 Million SEK | -219.85% |
| 2010 | -41.37 Million SEK | -441.16% |
| 2009 | -7.64 Million SEK | 95.72% |
| 2008 | -178.71 Million SEK | 38.71% |
| 2007 | -291.59 Million SEK | -5.5% |
| 2006 | -276.4 Million SEK | -6.11% |
| 2005 | -260.48 Million SEK | -209.22% |
| 2004 | -84.24 Million SEK | -444.12% |
| 2003 | -15.48 Million SEK | -4.26% |
| 2002 | -14.84 Million SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 324 Million SEK | 7.0% |
| 2024 Q2 | 343.3 Million SEK | 5.96% |
| 2024 Q3 | 458.9 Million SEK | 35.77% |
| 2023 FY | 302.8 Million SEK | -25.68% |
| 2023 Q1 | 388 Million SEK | -4.76% |
| 2023 Q3 | 294.5 Million SEK | 10.71% |
| 2023 Q4 | 302.8 Million SEK | 2.82% |
| 2023 Q2 | 266 Million SEK | -31.44% |
| 2022 Q1 | 109.1 Million SEK | 135.13% |
| 2022 FY | 407.4 Million SEK | 778.02% |
| 2022 Q4 | 407.4 Million SEK | -2.91% |
| 2022 Q2 | 300.1 Million SEK | 175.07% |
| 2022 Q3 | 419.6 Million SEK | 39.82% |
| 2021 Q2 | -125.2 Million SEK | 27.12% |
| 2021 Q1 | -171.8 Million SEK | 19.83% |
| 2021 FY | 46.4 Million SEK | 121.65% |
| 2021 Q4 | 46.4 Million SEK | 231.44% |
| 2021 Q3 | -35.3 Million SEK | 71.81% |
| 2020 Q3 | -305.9 Million SEK | 20.5% |
| 2020 Q4 | -214.3 Million SEK | 29.94% |
| 2020 Q1 | -537.5 Million SEK | -13.76% |
| 2020 Q2 | -384.8 Million SEK | 28.41% |
| 2020 FY | -214.3 Million SEK | 54.65% |
| 2019 Q1 | -261.2 Million SEK | 2.97% |
| 2019 FY | -472.5 Million SEK | -75.52% |
| 2019 Q4 | -472.5 Million SEK | -1.85% |
| 2019 Q3 | -463.9 Million SEK | -48.26% |
| 2019 Q2 | -312.9 Million SEK | -19.79% |
| 2018 Q3 | -196.4 Million SEK | -12.23% |
| 2018 Q1 | 25.2 Million SEK | 389.66% |
| 2018 Q2 | -175 Million SEK | -794.44% |
| 2018 FY | -269.2 Million SEK | -2994.25% |
| 2018 Q4 | -269.2 Million SEK | -37.07% |
| 2017 Q4 | -8.7 Million SEK | 71.1% |
| 2017 Q3 | -30.1 Million SEK | -165.86% |
| 2017 Q2 | 45.7 Million SEK | -48.54% |
| 2017 FY | -8.7 Million SEK | -107.54% |
| 2017 Q1 | 88.8 Million SEK | -23.05% |
| 2016 FY | 115.4 Million SEK | -61.04% |
| 2016 Q4 | 115.4 Million SEK | -47.35% |
| 2016 Q3 | 219.2 Million SEK | -9.65% |
| 2016 Q2 | 242.6 Million SEK | -7.37% |
| 2016 Q1 | 261.9 Million SEK | -11.58% |
| 2015 Q4 | 296.21 Million SEK | 1.27% |
| 2015 Q2 | 211 Million SEK | 2.03% |
| 2015 Q1 | 206.8 Million SEK | -1.19% |
| 2015 FY | 296.21 Million SEK | 41.54% |
| 2015 Q3 | 292.5 Million SEK | 38.63% |
| 2014 Q2 | 385.4 Million SEK | 39.89% |
| 2014 Q1 | 275.5 Million SEK | 17737.64% |
| 2014 Q3 | 196.9 Million SEK | -48.91% |
| 2014 Q4 | 209.28 Million SEK | 6.29% |
| 2014 FY | 209.28 Million SEK | 13498.34% |
| 2013 Q2 | 169 Million SEK | 686.05% |
| 2013 FY | -1.56 Million SEK | 98.64% |
| 2013 Q4 | -1.56 Million SEK | 94.96% |
| 2013 Q3 | -31 Million SEK | -118.34% |
| 2013 Q1 | 21.5 Million SEK | 118.78% |
| 2012 Q4 | -114.49 Million SEK | -382.01% |
| 2012 Q3 | 40.6 Million SEK | 255.56% |
| 2012 FY | -114.49 Million SEK | 13.49% |
| 2012 Q1 | -22.9 Million SEK | 82.7% |
| 2012 Q2 | -26.1 Million SEK | -13.97% |
| 2011 FY | -132.34 Million SEK | -219.85% |
| 2011 Q4 | -132.34 Million SEK | -90.52% |
| 2011 Q3 | -69.46 Million SEK | -322.94% |
| 2011 Q2 | -16.42 Million SEK | -107.25% |
| 2011 Q1 | 226.6 Million SEK | 647.65% |
| 2010 Q3 | 56.58 Million SEK | 5.07% |
| 2010 Q4 | -41.37 Million SEK | -173.13% |
| 2010 FY | -41.37 Million SEK | -441.16% |
| 2010 Q1 | 6.68 Million SEK | 187.43% |
| 2010 Q2 | 53.85 Million SEK | 705.56% |
| 2009 FY | -7.64 Million SEK | 95.72% |
| 2009 Q3 | -36.05 Million SEK | 0.0% |
| 2009 Q4 | -7.64 Million SEK | 78.79% |
| 2008 Q4 | -178.71 Million SEK | 0.0% |
| 2008 FY | -178.71 Million SEK | 38.71% |
| 2007 FY | -291.59 Million SEK | -5.5% |
| 2006 FY | -276.4 Million SEK | -6.11% |
| 2005 FY | -260.48 Million SEK | -209.22% |
| 2004 FY | -84.24 Million SEK | -444.12% |
| 2003 FY | -15.48 Million SEK | -4.26% |
| 2002 FY | -14.84 Million SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| AcuCort AB | -19.24 Million SEK | 1673.477% |
| AlzeCure Pharma AB (publ) | -29.1 Million SEK | 1140.55% |
| BioGaia AB (publ) | -1.53 Billion SEK | 119.721% |
| Enzymatica AB (publ) | 17.73 Million SEK | -1607.166% |
| Enorama Pharma AB (publ) | -5.71 Million SEK | 5396.484% |
| Gabather AB (publ) | -1.11 Million SEK | 27256.951% |
| Klaria Pharma Holding AB (publ.) | 17.68 Million SEK | -1612.185% |
| Moberg Pharma AB (publ) | -55.81 Million SEK | 642.477% |
| Nanexa AB (publ) | -61.13 Million SEK | 595.289% |
| Newbury Pharmaceuticals AB (publ) | -15.3 Million SEK | 2078.697% |
| ODI Pharma AB | -2.63 Million SEK | 11578.802% |
| Probi AB (publ) | -275.85 Million SEK | 209.769% |
| Swedencare AB (publ) | 1.42 Billion SEK | 78.696% |
| Swedish Orphan Biovitrum AB (publ) | 19.58 Billion SEK | 98.454% |
| Toleranzia AB | -17.45 Million SEK | 1834.846% |
| Vivesto AB | -1.29 Million SEK | 23410.239% |